Business consulting company Frost & Sullivan announced on Wednesday that WuXi AppTec has been awarded the 2025 Global Company of the Year Recognition in the contract research, development, and manufacturing organisation (CRDMO) industry for its outstanding achievements in enabling innovation, operational excellence, and customer impact.
Based in China, WuXi AppTec is a global pharmaceutical CRDMO that provides integrated drug discovery, development and manufacturing services across Asia, Europe and North America.
This award highlights WuXi AppTec's contribution to driving scientific and technological advancement through an integrated, end-to-end CRDMO model, enabling customers and partners worldwide to accelerate the journey from discovery to patient-ready therapies, Frost & Sullivan said.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA